The legacy of ISCHEMIA by Ianni, Umberto et al.
Address for correspondence:  Marco Zimarino, MD, PhD, Institute of Cardiology, “G. d’Annunzio” University,  
c/o Ospedale SS. Annunziata, Via dei Vestini, 66013 Chieti, Italy, tel: +39-0871-41512, fax: +39-0871-402817,  
e-mail: mzimarino@unich.it
The legacy of ISCHEMIA
Umberto Ianni1, Francesco Radico1, Fabrizio Ricci2, 3, Matteo Perfetti4,  
Federico Archilletti1, Giulia Renda1, 3, Nicola Maddestra4, Sabina Gallina1, Marco Zimarino1, 4
1Institute of Cardiology, ”G. d’Annunzio” University, Chieti, Italy 
2Department of Clinical Sciences, Lund University, Clinical Research Center, Malmö, Sweden 
3Department of Neuroscience, Imaging and Clinical Sciences, “G. d’Annunzio” University, Chieti, Italy 
4Interventional Cath Lab, ASL 2 Abruzzo, Chieti, Italy
Main findings of the 
ISCHEMIA trial
The long-awaited 
results of the ISCHEMIA 
(International Study 
of Comparative Health 
Ef fec t iveness  wi th 
Medical and Invasive 
Approaches) trial were 
recently made available 
in the ‘New England 
Journal of Medicine’ [1, 2]. Two main manuscripts 
detailed on a composite endpoint of death from 
cardiovascular causes, myocardial infarction (MI), 
hospitalization for unstable angina, heart failure, 
or resuscitated cardiac arrest [1] and on quality 
of life assessment [2]. Overall, the ISCHEMIA 
trial encompassing 5179 randomized patients with 
chronic coronary syndromes (CCS), documented 
that the risk of the primary composite endpoint is 
similar for an initial invasive strategy with coro-
nary angiography and revascularization, either by 
percutaneous coronary intervention (PCI) or by 
coronary artery bypass grafting (CABG) and an 
initial conservative strategy with optimal medical 
therapy (OMT) (Fig. 1A) [1]. An initial invasive 
strategy clearly produced a greater improvement in 
angina-related health status (Fig. 2) [2]. As for the 
occurrence of adverse events, when compared with 
an initial conservative approach, the invasive strat-
egy was associated with an early increased risk, 
seemingly derived from periprocedural events, 
that waned and even in-
verted in the long term, 
showing a trend towards 
a protective effect [1]. 
Such results were 
in line with previous 
findings in patients with 
CCS from COURAGE 
(Clinical Outcomes Uti-
lizing Revascularization 
and Aggressive Drug 
Evaluation) [3] and 
ORBITA (Objective Randomized Blinded Investiga-
tion with optimal medical Therapy of Angioplasty 
in stable angina) [4] trials. However, the idea that 
sicker patients, with more disease or more ischemia, 
would do better with revascularization has not been 
questioned, as the high-risk population — patients 
with unprotected left main disease, impaired sys-
tolic function, heart failure, recent acute coronary 
syndromes and/or Canadian Cardiovascular Society 
class III or IV angina of recent onset — were quite 
reasonably excluded from the trial.
Amendments and limitations  
of eligibility criteria
The initial plan was to conduct an interna-
tional, multi-center randomized trial in 8000 CCS 
patients, comparing early invasive management 
followed by routine revascularization with OMT 
and revascularization only in case of persistent 
symptoms or MI [5]. 
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This trial design was elegant and designed 
originally with hard primary endpoints, which 
would have offered a definitive answer. Random-
ization to conservative or invasive strategies was 
carried out after coronary computed tomographic 
angiographic (CCTA), before coronary angiography, 
thus preventing physicians from a withdrawing-bias 
in patients with lesions suitable for immediate 
stenting. The trial was started in July 2012, but 
investigators soon realized that the recruitment 
was slow and event rates lower than anticipated. 
Consequently, several substantial changes were 
applied to both the design and the primary endpoint 
to complete the trial. 
Figure 2. Effect of the invasive strategy on symptoms, estimated as the mean difference of invasive versus conserva-
tive strategy on Seattle Angina Questionnaire (SAQ) summary scores, according to baseline angina burden during 
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Figure 1. Clinical endpoints differences between treatment groups across a 5-year follow-up and relative estimated 
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The definition of the ischemic burden was 
central to the primary hypothesis, that extent 
and severity of ischemia are related to adverse 
outcomes in CCS, as documented in the COUR-
AGE trial nuclear substudy [6], where patients 
with ischemia reduction had a lower risk of death 
or MI, mainly if baseline ischemia was moderate-
to-severe (≥ 10% myocardium). The laudable in-
tention that moved the ISCHEMIA investigators 
to enroll only patients with moderate-to-severe 
ischemia, having rigorous documentation by stress 
imaging assessment as single-photon emission 
computed tomography or stress-echocardiography 
or stress-cardiac magnetic resonance, was later 
aborted forcefully. In order to expedite recruitment, 
patients with a lesser amount of ischemia (≥ 5% 
myocardium) or with documentation of ischemia 
on the sole electrocardiogram-exercise test — 
a diagnostic modality with a much lower diagnostic 
sensibility — were deemed eligible, reaching the 
minimal threshold for the predefined power but 
tarnishing the original ambitious aim. Arguably, the 
severity of ischemia cannot be measured without 
imaging, and the lack of standardized grading and 
inconsistency in reporting of the extent and se-
verity of ischemia across different stress imaging 
modalities raise major concerns on the accuracy 
of ischemic burden quantification and patient se-
lection [7, 8]. Furthermore, according to the main 
study protocol, almost one-third of randomized 
patients with estimated glomerular filtration rate 
(eGFR) < 60 mL/min with a “high likelihood” of 
significant left main disease based on the results 
of the stress test did not undergo CCTA due to the 
risk of contrast-induced nephropathy. In this case, 
trial eligibility relied on the physician determina-
tion, carrying a subjective component in the diag-
nostic pathway and ultimately introducing another 
potential source of selection bias.
There is also a major concern about the over-
interpretation of the ISCHEMIA trial design in 
clinical practice, where a problematic reading may 
result in extrapolating beyond the data provided 
in the study [9]. This is the case when advocating 
CCTA as the first-line strategy in all patients with 
chest pain, regardless of the pre-test likelihood of 
coronary artery disease (CAD) and demonstration 
of ischemia. In the ISCHEMIA trial, CCTA was pri-
marily aimed at ruling out the presence of significant 
unprotected left main disease — but surprisingly not 
a proximal three-vessel disease — and to confirm 
the presence of obstructive CAD in patients with 
at least moderate ischemia. Claiming that CCTA 
should be performed at a population level where the 
prevalence of the left main disease is predictably low 
has the potential of exposing a significant number 
of patients to ionizing radiation and nephrotoxic 
contrast agents, when alternative and more cost-
effective options are available [10, 11].
Finally, about 14% of patients enrolled failed 
to meet eligibility criteria for ischemia at a later 
core laboratory evaluation, but they were part of 
the study population anyway; this cohort showed 
a trend towards an increased benefit from the 
conservative strategy, further flawing the main 
findings of the study.
Changing the primary endpoint:  
A contingency plan
The ISCHEMIA trial was conducted in ac-
cordance with the most rigorous clinical trial 
standards, and investigators should be commended 
for preparing a contingency plan in case of lower 
than expected event rates for the original primary 
endpoint of cardiovascular death or MI. This pre-
specified back-up strategy was vital in avoiding 
a common pitfall of other trials, namely lower-than-
projected power because of lower than anticipated 
event rates. It led to the 5-component endpoint, 
including cardiovascular death, MI, hospitalization 
for unstable angina, resuscitated cardiac arrest, 
or heart failure, as per the original grant proposal 
awarded by National Heart, Lung, and Blood Insti-
tute (NHLBI) in 2011 [8].
Accordingly, projections in 2015, using up-
dated assumptions for the randomization rate and 
demonstrating an enrollment rate lagging behind 
timelines and lower than expected adverse events, 
suggested that the intended goals needed bet-
ter calibration in favor of a more reasonable and 
pragmatic target. The sample size was therefore 
lowered by nearly 35% and the mean follow-up 
duration by 25% (from 4 to 3.2 years). However, 
activation of the contingency plan had a price to 
pay. Indeed, by dropping the prespecified power 
threshold below 90%, investigators were facing 
two alternatives: either reporting an underpow-
ered trial with a negative prespecified primary 
outcome, or a potentially false-positive trial with 
“re-engineered” alternative outcomes [12].
For the multinational ISCHEMIA trial, con-
ducted at 320 sites in 37 countries, investigators 
obtained 108 million USD from NHLBI, based on 
the recognition that trial results would have al-
lowed saving of > 500 million USD/year from the 
reduction of unnecessary revascularization, clearly 
exceeding the public fund earmarked [12].
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The publication of the trial spurred contro-
versy among the scientific community [13].
As claimed by Antman and Braunwald [14], the 
most obvious conclusion is that the two strategies 
seem to have similar efficacy. At the same time, the 
patients in the invasive-strategy group reported 
substantially fewer angina symptoms than those in 
the conservative approach. However, the magni-
tude of this benefit depended on angina frequency 
at baseline, with 35% of cases being asymptomatic. 
Possible reasons for such similar findings are the 
low-risk of the study population and the potential 
effect of practice patterns that may have excluded 
more symptomatic patients. In the main trial, the 
incidence of the primary outcome was sensitive to 
the definition of MI, with a substantial prevalence of 
periprocedural MIs in the early follow-up favoring 
a conservative strategy and higher incidence of 
spontaneous MIs in a later course, when the inva-
sive approach showed a protective effect. Investiga-
tors adjudicated MI employing a primary or second-
ary definition, the latter using references from the 
assay manufacturer’s package insert and including 
contingencies to allow diagnosing MI despite 
whether  they had various elements of the medical 
record missing. For spontaneous MI, investigators 
adopted the third universal definition of MI (types 
1, 2, 4b, 4c), while for procedural MI (types 4a, 5) 
creatine kinase myocardial band (CK-MB) was the 
preferred biomarker and higher thresholds were 
used: (i) post-PCI, a rise in CK-MB > 5-fold the 
upper limit of normal (ULN) or a rise in troponin 
> 35-fold the ULN post-PCI; (ii) post-CABG, a rise 
in CK-MB > 10-fold the ULN or a rise in troponin 
> 70-fold the ULN post-PCI. Investigators adopted 
such thresholds with the aim of compensating for 
the reduced prognostic relevance of periprocedural 
as compared to spontaneous MI [15]. A similar 
controversy recently animated the presentation of 
the 5-year outcomes of the EXCEL (Evaluation of 
XIENCE versus Coronary Artery Bypass Surgery 
for Effectiveness of Left Main Revascularization) 
trial [16]. Finally, the adoption of a definition of 
periprocedural MI for both PCI and CABG based 
on CK rise > 10-fold the ULN or > 5-fold the ULN 
with new Q-waves, angiographic vessel occlusion, 
or loss of myocardium on imaging was strongly as-
sociated with increased 3-year mortality even after 
controlling for potential confounders [17].
In the ISCHEMIA trial, the invasive strategy 
was associated with a trend towards a reduced 
incidence of death from cardiovascular causes or 
MI (16.5% vs. 14.9%), as was the primary defini-
tion of the study, and a significant absolute risk 
reduction of 2.9% of spontaneous MI at 5 years 
(Fig. 1B) [1]. Antman and Braunwald [14] hy-
pothesized as well that ISCHEMIA might have 
ended before a substantial difference in favor of 
the invasive strategy had emerged. As therapeutic 
benefits tend to wane at longer follow-up in aging 
populations, authors herein, respectfully disagree 
that prolonging of the study would have unveiled 
such a difference; nevertheless, by considering 
a calculated event rate of 3.3 per 100 person-
years in the invasive group and of 3.8 per 100 
person-years, with a type I error of 5% (a = 0.05) 
and a statistical power of 80%, the study popula-
tion should have been followed-up for 6.5 years 
overall. Alternatively, the same difference in the 
hard-end points would have been detected with 
a population of about 8000 patients per group, 
obviously requiring a far larger resource allocation 
for the trial.
Group comparisons were performed accord-
ing to the intention-to-treat principle that counts 
crossovers within originally assigned groups, 
regardless of the treatment actually received. 
However, no adjustment for non-adherence to the 
randomized treatment strategy, such as censoring 
at the time of crossover, was considered as deemed 
susceptible to bias as per the study protocol. After 
randomization, 16% of patients in the invasive arm 
did not receive any revascularization, while 21% 
of patients in the conservative-strategy group 
underwent revascularization, therefore resulting 
in a bidirectional crossover likely driving potential 
underestimation of the actual long-term benefit of 
the invasive approach. However, the prespecified 
aim of the study was to test the initial management 
strategy, and, in this view, the intensity of crosso-
ver was acceptable despite an invasive approach, 
which was later pursued in more than one-fourth 
of the study population. Nevertheless, the intense 
crossover rate observed in ISCHEMIA, along with 
slow enrollment, would suggest that keeping an 
ischemic patient away from revascularization for 
quite a while can be somewhat tricky in the absence 
of a sham group as in ORBITA [4]. 
Special subgroups
Chronic kidney disease
Patients with advanced chronic kidney disease 
(CKD) have been systematically excluded or only 
marginally included in most trials on cardiovascular 
disease, thus preventing a confident estimation 
of treatment benefits [18]. Patients with advance 
CKD, defined as an eGFR < 30 mL/min/1.73 m2 of 
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the body surface area or on dialysis, and moderate 
or severe myocardial ischemia were investigated 
in the ISCHEMIA-CKD (Management of Coronary 
Disease in Patients with Advanced Kidney Disease) 
trial [19]. In contrast with the main trial, the use 
of CCTA angiography was not recommended as 
a screening test because of the potential risk of 
acute kidney injury. Therefore, no core-laboratory 
was used for validation. After a median of 2.2-year 
follow-up, the primary endpoint — a composite of 
death and non-fatal MI — was similar in the two 
groups. The invasive arm experienced a higher 
incidence of non-procedural stroke and new dialysis 
initiation. Overall, ISCHEMIA findings have been 
confirmed even in the CKD population, pending 
a few considerations. Firstly, the exclusion of patients 
with reduced ejection fraction and/or refractory an-
gina could have prevented the potential benefits of 
revascularization. Secondly, the selection of frail and 
comorbid patients with compromised status could be 
itself a proxy for futility, where mortality was high 
(27% at 3 years) in both subgroups, and coronary 
angiography not performed in 15% of the patients 
allocated in the invasive arm. Thirdly, selection cri-
teria poorly identified ischemic patients amenable to 
revascularization, as in the invasive strategy group 
only 50% of patients underwent revascularization, 
and the absence of obstructive CAD was documented 
in one-quarter of the cohort. Beyond confirming the 
poor outcome of patients with CKD, ISCHEMIA-CKD 
results highlighted the modest positive predictive 
value of stress testing for the detection of obstructive 
epicardial CAD, while suggesting a high prevalence 
and prognostic significance of coronary microvascular 
disease in CKD patients with CCS [20].
Ischemia with no obstructive  
coronary artery disease 
Almost 20% of screened patients were ex-
cluded from the ISCHEMIA trial for the absence 
of clear imaging evidence of obstructive coronary 
disease by CCTA. If they were complaining of 
ischemic symptoms, they merged into the aligned 
CIAO-ISCHEMIA (Changes in Ischemia and An-
gina over One year among ISCHEMIA) trial. Al-
though not yet available in a full-length manuscript, 
these data were recently presented at the American 
College of Cardiology 2020 Scientific Session [21], 
enquire an interesting target population, with a high 
prevalence of women (66% in CIAO-ISCHEMIA 
compared with 26% in ISCHEMIA with obstructive 
CAD, p < 0.001). Despite controversial data, such 
patients now seem to portend a heterogeneous but 
in general benign prognosis, similar to that of the 
general population, with the presence of “some” 
coronary atherosclerosis being the main outcome 
determinant [22]. However, CIAO-ISCHEMIA was 
designed to test changes in ischemia and angina 
symptoms in the population of ischemia and no 
obstructive coronary artery disease (INOCA) and 
is not powered to test hard cardiovascular events. 
At 1 year, in patients in CIAO-ISCHEMIA, stress 
echocardiograms became normal in about half 
of patients, and in 45% of cases, they were the 
same as at baseline or worse. Angina symptoms 
improved in 42% and worsened in 14% of patients, 
and the number of medications to control angina 
on average remained the same. Interestingly, the 
change in stress test findings and the change in 
symptoms over 1 year were not related. These 
findings seem to reject the hypothesis that the 
extent of myocardial ischemia is responsible for 
angina in INOCA patients, suggesting that un-
measured determinants would contribute to patient 
symptoms, possibly including sensory, emotional, 
autonomic, motor, cognitive and other sex-related 
components. Again, the association among angina, 
coronary atherosclerosis and myocardial ischemia 
has confirmed to be exceedingly elusive. 
The extent of revascularization  
in multivessel coronary artery disease
Since the benefit of revascularization is di-
rectly proportional to the extent of ischemia and 
of the atherothrombotic burden provoking it, then 
the management of patients with multivessel CAD 
should be prioritized. In this cohort, there is ex-
tensive evidence that complete revascularization 
confers a more considerable clinical benefit [23], 
mostly when performed with state-of-the-art tech-
niques, namely second or third generation drug-
eluting stent (DES) and extensive use of arterial 
conduits for CABG [24]. However, while complete 
revascularization has outlined a relevant advantage 
in the setting of an acute coronary syndrome, 
such benefit has not yet been proven in CCS. The 
ISCHEMIA trial would have been a milestone in this 
view. A comprehensive definition of the adequacy 
of myocardial revascularization should take into 
account the size of the vessel, the severity of the le-
sion, the ischemic burden caused by the lesion, and 
the viability of the depending myocardial territory 
[25]. The quality of the design in the ISCHEMIA 
trial is also evidenced by the availability of two 
separate flow-charts, to guide the invasive strat-
egy in both imaging and non-imaging subgroups. 
The use of fractional flow reserve was strongly 
recommended [26, 27], and most of the revascu-
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larization procedures were performed according to 
best practice evidence, with > 90% last-generation 
DES for PCI and internal mammary arteries for 
CABG [1]. The benefit of the invasive approach, 
albeit still not significant, was proportional to the 
extent of CAD. Unfortunately, details regarding the 
adequacy and methods of revascularization are yet 
not available, and the scientific community yearn-
ingly awaits such data for further argumentations. 
As an example, it would be interesting to know the 
prevalence of bifurcations and chronic total occlu-
sions on the total amount of PCI performed in both 
conservative and invasive strategy groups [28], as 
lesion complexity seems to affect periprocedural and 
long-term outcomes [29, 30], and to have a relevant 
implication on the subsequent dual antiplatelet 
therapy [31, 32] as well. Similarly, the complexity of 
the revascularization treatment might have affected 
the outcome [33].
In this view, the dataset deriving from the 
ISCHEMIA trial would be extremely valuable to 
explore the impact of lesion complexity and the opti-
mal duration of antiplatelet therapy on the outcome. 
Conclusions
The ISCHEMIA trial highlighted many chal-
lenges that cardiologists experience during their 
daily practice in the diagnosis and management 
of CCS, and it also delivered reassurance that 
for patients with at least moderate ischemia and 
acceptable symptoms who meet the trial criteria, 
invasive management may be reasonably deferred 
during optimal titration of OMT. While an extended 
follow-up of the ISCHEMIA trial would be highly 
informative and as new cardiac imaging techniques 
for fully-quantitative assessment of myocardial per-
fusion appear on the horizon, further prospective 
research should investigate whether longitudinal 
changes in adverse coronary plaque characteris-
tics and whether ischemic burden associated with 
more intensive treatment would reduce the risk 
of ischemic events.
While guidelines continue to suggest that 
revascularization should be offered at an earlier 
stage to patients with the highest ischemia burden 
[34], the question of whether ischemia truly mat-
ters and how revascularization affects outcomes 
remains unsolved [35].
The view herein, holds that the legacy of 
the ISCHEMIA trial is two-fold: firstly, reiterat-
ing the crucial value of randomized controlled 
trials, which must be done before hypotheses 
become false certainties; secondly, recalling the 
“courage” to follow a pathway, once it has been 
designed, without hesitation, regardless the ex-
pected effects.
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